The majority of previous studies have reported that patients with T2DM had low levels of irisin and that irisin might be a biomarker with plausible predictive values for clinical outcomes, although there are controversial issues [17,25,26]. This evidence concerns the gene FNDC5 and type 2 diabetes mellitus.